Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citation
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
“Type I IFNs are critical for antiviral and antitumour responses in healthy cells not only because they promote immune responses to clear the virus, but also because they reduce cellular proliferation and activate the proapoptotic protein p53 (REF. 62 ).”
BackgroundCytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
“Finally, the apoptosis-activating gene p53 is also IFN-inducible and can be activated indirectly in response to dsRNA or virus infection to trigger an apoptotic response (Takaoka et al., 2003).”
BackgroundInfluentialCancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
“, can upregulate the p53-mediated response of tumour cell”
BackgroundThe cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280
The IRF Family Transcription Factors in Immunity and Oncogenesis
Tamura, T., Yanai, H., Savitsky, D., & Taniguchi, T. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090400 · Cited by 1,259
Self-citationWark, P. A. B., Johnston, S. L., Bucchieri, F., Powell, R., Puddicombe, S., Laza-Stanca, V., Holgate, S. T., & Davies, D. E. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041901 · Cited by 1,235
“Release of interferon- from BECs after infection Because IFN- / has recently been shown to induce apoptotic responses in antiviral immunity (11), and because IFNis known to be secreted first and to strongly induce the IFN- subfamily (15), we investigated whether impaired production of IFN- was the underlying mechanism…”
BackgroundInfluentialType I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
Theofilopoulos, A. N., Baccala, R., Beutler, B., & Kono, D. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115843 · Cited by 1,185
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors
Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., Kano, S.-I., Honda, K., Ohba, Y., Mak, T. W., et al. (2005) · Nature · doi:10.1038/nature03308 · Cited by 1,039
Self-citationKolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J., & Murali-Krishna, K. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050821 · Cited by 965
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Self-citationWhy do viruses cause cancer? Highlights of the first century of human tumour virology
Moore, P. S., & Chang, Y. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2961 · Cited by 745
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
Phan, R. T., & Dalla-Favera, R. (2004) · Nature · doi:10.1038/nature03147 · Cited by 679
“Analogous to most cell types, control-transduced clones express extremely low levels of p53 mRNA (detectable only after 30 cycles of polymerase chain reaction (PCR)-mediated amplification) under basal conditions, because p53 expression is induced by genotoxic stres”
BackgroundPDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
The airway epithelium: soldier in the fight against respiratory viruses
Vareille, M., Kieninger, E., Edwards, M. R., & Regamey, N. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-10 · Cited by 655
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Inflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640
p53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
Interferon signalling network in innate defence
Takaoka, A., & Yanai, H. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00716.x · Cited by 581
Self-citationPUMA, a potent killer with or without p53
Yu, J., & Zhang, L. (2008) · Oncogene · doi:10.1038/onc.2009.45 · Cited by 554
“Other immune modulators such as interferons can stimulate PUMA expression through p53 or Jak1 (Takaoka et al., 2003; Gomez-Benito et al., 2007).”
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
Major, J., Crotta, S., Llorian, M., McCabe, T. M., Gad, H. H., Priestnall, S. L., Hartmann, R., & Wack, A. (2020) · Science · doi:10.1126/science.abc2061 · Cited by 503
TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells
Salaun, B., Coste, I., Rissoan, M.-C., Lebecque, S. J., & Renno, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4894 · Cited by 479
PML and PML nuclear bodies: Implications in antiviral defence
Everett, R. D., & Chelbi-Alix, M. K. (2007) · Biochimie · doi:10.1016/j.biochi.2007.01.004 · Cited by 439
Besch, R., Poeck, H., Hohenauer, T., Senft, D., Häcker, G., Berking, C., Hornung, V., Endres, S., Ruzicka, T., Rothenfusser, S., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37155 · Cited by 433
A complex barcode underlies the heterogeneous response of p53 to stress
Murray-Zmijewski, F., Slee, E. A., & Lu, X. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2451 · Cited by 420
Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications
Jin, M. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0196-9 · Cited by 413
Acute exacerbations of asthma: epidemiology, biology and the exacerbation‐prone phenotype
Dougherty, R. H., & Fahy, J. V. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03157.x · Cited by 396
Type I Interferon Sensitizes Lymphocytes to Apoptosis and Reduces Resistance to Listeria Infection
Carrero, J. A., Calderon, B., & Unanue, E. R. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040769 · Cited by 390
Mechanisms and Regulation of Cellular Senescence
Roger, L., Tomas, F., & Gire, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313173 · Cited by 395
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
BackgroundRegulation of the type I IFN induction: a current view
Honda, K., Yanai, H., Takaoka, A., & Taniguchi, T. (2005) · International Immunology · doi:10.1093/intimm/dxh318 · Cited by 348
Self-citationMutant p53 suppresses innate immune signaling to promote tumorigenesis
Ghosh, M., Saha, S., Bettke, J., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 348
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Muñoz-Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.99 · Cited by 341
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
“Jo u rn al o f Ce ll Sc ie n ce macrophage migration inhibitory factor inhibit p53 as a mechanism to escape cell death and senescence (Fingerle-Rowson et al., 2003; Hodge et al., 2005; Hudson et al., 1999; Mañes et al., 2003; Niu et al., 2005; Takaoka et al., 2003; Yonish-Rouach et al., 1991).”
BackgroundPietras, E. M., Lakshminarasimhan, R., Techner, J.-M., Fong, S., Flach, J., Binnewies, M., & Passegué, E. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131043 · Cited by 323
Signal transduction of inflammatory cytokines and tumor development
Yoshimura, A. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00197.x · Cited by 314
PML Is a Direct p53 Target that Modulates p53 Effector Functions
de Stanchina, E., Querido, E., Narita, M., Davuluri, R. V., Pandolfi, P. P., Ferbeyre, G., & Lowe, S. W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00062-0 · Cited by 312
“Therefore, nucleotide of exon 1 of PML was assigned position 5000, as shown in Figure 5A. Genomic DNA isolated from wt MEFs was amplifiedIFN and p53 regulate PML through distinct mechanisms. by PCR in the presence of 5% DMSO.”
BackgroundInfluentialOvercoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment
Coussens, A. K., Wilkinson, R. J., Hanifa, Y., Nikolayevskyy, V., Elkington, P. T., Islam, K., Timms, P. M., Venton, T. R., Bothamley, G. H., Packe, G. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200072109 · Cited by 310
Regulation of immunity and oncogenesis by the IRF transcription factor family
Savitsky, D., Tamura, T., Yanai, H., & Taniguchi, T. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0804-6 · Cited by 298
Self-citationThe CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis
Knippschild, U., Krüger, M., Richter, J., Xu, P., GarcÃa-Reyes, B., Peifer, C., Halekotte, J., Bakulev, V., & Bischof, J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00096 · Cited by 272
Evolution of the Papillomaviridae
Van Doorslaer, K. (2013) · Virology · doi:10.1016/j.virol.2013.05.012 · Cited by 261
DawnRank: discovering personalized driver genes in cancer
Hou, J. P., & Ma, J. (2014) · Genome Medicine · doi:10.1186/preaccept-1835019729127471 · Cited by 273
Berger Rentsch, M., & Zimmer, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025858 · Cited by 269
“Genetically engineered type I IFNs are currently in clinical use for the treatment of multiple sclerosis [6] , chronic hepatitis C virus infection [7] , and certain types of cancer [8, 9] .”
BackgroundGal-Ben-Ari, S., Barrera, I., Ehrlich, M., & Rosenblum, K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00480 · Cited by 254
Type I interferons: crucial participants in disease amplification in autoimmunity
Hall, J. C., & Rosen, A. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.237 · Cited by 265
The IRF family of transcription factors: Inception, impact and implications in oncogenesis
Yanai, H., Negishi, H., & Taniguchi, T. (2012) · OncoImmunology · doi:10.4161/onci.22475 · Cited by 261
Self-citationDNA damage-induced type I interferon promotes senescence and inhibits stem cell function
Yu, Q., Katlinskaya, Y. V., Carbone, C. J., Zhao, B., Katlinski, K. V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.069 · Cited by 260
Obi, S., Yoshida, H., Toune, R., Unuma, T., Kanda, M., Sato, S., Tateishi, R., Teratani, T., Shiina, S., & Omata, M. (2006) · Cancer · doi:10.1002/cncr.21832 · Cited by 262
DNA Damage Signaling and p53-dependent Senescence after Prolonged β-Interferon Stimulation
Moiseeva, O., Mallette, F. A., Mukhopadhyay, U. K., Moores, A., & Ferbeyre, G. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-09-0858 · Cited by 252
The DNA Damage Response Induces IFN
Brzostek-Racine, S., Gordon, C., Van Scoy, S., & Reich, N. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100040 · Cited by 234
Pathogenesis and Host Control of Gammaherpesviruses: Lessons from the Mouse
Barton, E., Mandal, P., & Speck, S. H. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-072710-081639 · Cited by 246
“Intrinsic and innate immune responses may be coordinately regulated and are therefore treated together here (134).”
BackgroundTranscriptional role of p53 in interferon-mediated antiviral immunity
Muñoz-Fontela, C., Macip, S., Martínez-Sobrido, L., Brown, L., Ashour, J., García-Sastre, A., Lee, S. W., & Aaronson, S. A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080383 · Cited by 244
“Also, it has been recently reported that cells that conserve p53 functions show an increase in p53-dependent apoptosis in response to viral infection, which is associated with reduced viral replication ( 4, 9 ).”
InfluentialHerbeuval, J.-P. (2005) · Blood · doi:10.1182/blood-2005-03-1243 · Cited by 211
Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression
Yanai, H., Chen, H.-M., Inuzuka, T., Kondo, S., Mak, T. W., Takaoka, A., Honda, K., & Taniguchi, T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611559104 · Cited by 216
Self-citationUsing or abusing: viruses and the cellular DNA damage response
Lilley, C. E., Schwartz, R. A., & Weitzman, M. D. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.01.003 · Cited by 207
Khaitov, M. R., Laza‐Stanca, V., Edwards, M. R., Walton, R. P., Rohde, G., Contoli, M., Papi, A., Stanciu, L. A., Kotenko, S. V., & Johnston, S. L. (2009) · Allergy · doi:10.1111/j.1398-9995.2008.01826.x · Cited by 209
Toll-like Receptor 3 Expressed by Melanoma Cells as a Target for Therapy?
Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D., & Romero, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0274 · Cited by 204
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis
Boasso, A., & Shearer, G. M. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.015 · Cited by 206
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans
Ochi, A., Graffeo, C. S., Zambirinis, C. P., Rehman, A., Hackman, M., Fallon, N., Barilla, R. M., Henning, J. R., Jamal, M., Rao, R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63606 · Cited by 199
HIV-1 immunopathogenesis: How good interferon turns bad
Herbeuval, J.-P., & Shearer, G. M. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.09.016 · Cited by 190
Opposing Roles of Type I Interferons in Cancer Immunity
Boukhaled, G. M., Harding, S., & Brooks, D. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-031920-093932 · Cited by 191
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 190
Role of Promyelocytic Leukemia Protein in Host Antiviral Defense
Geoffroy, M.-C., & Chelbi-Alix, M. K. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0111 · Cited by 185
Chlamydia and apoptosis: life and death decisions of an intracellular pathogen
Byrne, G. I., & Ojcius, D. M. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1007 · Cited by 196
“pl?P04637">p53 , which is an important growth-arrest transcription factor and apoptosis inducer, and thereby increase the neoplastic potential of these viruses by reducing the potential of the host cell for apoptosi”
BackgroundHardy, A. W., Graham, D. R., Shearer, G. M., & Herbeuval, J.-P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707244104 · Cited by 173
The Role of Protein Kinase R in the Interferon Response
Pindel, A., & Sadler, A. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0099 · Cited by 180
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 182
The IKK-related kinases: from innate immunity to oncogenesis
Clément, J.-F., Meloche, S., & Servant, M. J. (2008) · Cell Research · doi:10.1038/cr.2008.273 · Cited by 185
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness
Furman, D., Jojic, V., Kidd, B., Shen‐Orr, S., Price, J., Jarrell, J., Tse, T., Huang, H., Lund, P., Maecker, H. T., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.15 · Cited by 184
Toll‐like receptors’ two‐edged sword: when immunity meets apoptosis
Salaun, B., Romero, P., & Lebecque, S. (2007) · European Journal of Immunology · doi:10.1002/eji.200737744 · Cited by 179
Pharmacology and therapeutic potential of interferons
George, P. M., Badiger, R., Alazawi, W., Foster, G. R., & Mitchell, J. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.006 · Cited by 176
Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
Jhawar, S. R., Thandoni, A., Bommareddy, P. K., Hassan, S., Kohlhapp, F. J., Goyal, S., Schenkel, J. M., Silk, A. W., & Zloza, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00202 · Cited by 178
Jeon, Y. J., Yoo, H. M., & Chung, C. H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.02.006 · Cited by 172
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Type I Interferons and Natural Killer Cell Regulation in Cancer
Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 160
“Type i iFNs in Tumor Development Type I IFNs have been shown to prevent cellular transformation in premalignant cells in vitro by sustaining the expression of the tumor suppressor gene p53 (20).”
BackgroundSelf-citationControl of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling
Zhirnov, O. P., & Klenk, H.-D. (2007) · Apoptosis · doi:10.1007/s10495-007-0071-y · Cited by 168
Sedaghat, A. R., German, J., Teslovich, T. M., Cofrancesco, J., Jie, C. C., Talbot, C. C., & Siliciano, R. F. (2008) · Journal of Virology · doi:10.1128/jvi.02228-07 · Cited by 161
Bergounioux, J., Elisee, R., Prunier, A., Donnadieu, F., Sperandio, B., Sansonetti, P. J., & Arbibe, L. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.01.013 · Cited by 178
Molecular Basis of Coronavirus Virulence and Vaccine Development
Enjuanes, L., Zuñiga, S., Castaño-Rodriguez, C., Gutierrez-Alvarez, J., Canton, J., & Sola, I. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.003 · Cited by 159
“HCoV-NL63 PLP2 DUB activity seems to be involved in modulation of NF-kB activation (Clementz et al., 2010) and p53-mediated modulation of IFN production (Takaoka et al., 2003) .”
BackgroundMancl, M. E., Hu, G., Sangster‐Guity, N., Olshalsky, S. L., Hoops, K. E. M., Fitzgerald-Bocarsly, P. A., Pitha, P. M., Pinder, K. E., & Barnes, B. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500543200 · Cited by 178
Influenza Virus Infection Increases p53 Activity: Role of p53 in Cell Death and Viral Replication
Turpin, E., Luke, K., Jones, J., Tumpey, T., Konan, K., & Schultz-Cherry, S. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.8802-8811.2005 · Cited by 160
Role of Redox Status in Development of Glioblastoma
Salazar, A., Ortega, D. R., de la Cruz, V. P., Hernández‐Pedro, N., González‐Esquivel, D. F., Sotelo, J., & Pineda, B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00156 · Cited by 170
Natsume, A., Ishii, D., Wakabayashi, T., Tsuno, T., Hatano, H., Mizuno, M., & Yoshida, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0036 · Cited by 171
“Cell lysis and immunoblotting were carried out as described (11).”
BackgroundInterferon regulatory factor family of transcription factors and regulation of oncogenesis
Takaoka, A., Tamura, T., & Taniguchi, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00720.x · Cited by 172
Self-citationUnderstanding and altering cell tropism of vesicular stomatitis virus
Hastie, E. L., Cataldi, M. P., Marriott, I., & Grdzelishvili, V. Z. (2013) · Virus Research · doi:10.1016/j.virusres.2013.06.003 · Cited by 160
TRIM25 in the Regulation of the Antiviral Innate Immunity
Martin‐Vicente, M., Medrano, L. M., Resino, S., García‐Sastre, A., & Martínez, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01187 · Cited by 160
Antiviral activity of resveratrol
Campagna, M., & Rivas, C. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380050 · Cited by 149
Pateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 156
“Takaoka et al. (2003) clearly proved that IFNα/β signaling promotes p53 in turn evoking apoptosis that is critical for antiviral immunity, thus showing a novel link between IFNs and p53 in antiviral immunity and tumor suppression.”
BackgroundKim, K. S., Kang, K. W., Seu, Y. B., Baek, S., & Kim, J.-R. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.11.004 · Cited by 164
Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL
Clarke, N., Jimenez-Lara, A. M., Voltz, E., & Gronemeyer, H. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600302 · Cited by 163
“Moreover, the synergy between IRF-1 and p53 should be reconsidered in view of the p53-induced expression of the TRAIL receptor DR5 (Wu et al, 1997; Kim et al, 2001; Wang and El-Deiry, 2003a) and the observation that IFNs induce p53 at the transcriptional level (Takaoka et al, 2003).”
BackgroundÔta, H., Nagano, H., Sakon, M., Eguchi, H., Kondo, M., Yamamoto, T., Nakamura, M., Damdinsuren, B., Wada, H., Marubashi, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602742 · Cited by 145
Viruses and the Diversity of Cell Death
Danthi, P. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042435 · Cited by 158
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.